NCT02272998 2025-03-24
Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
Clinical Trials
3 trialsNCT00336076 2016-11-07
Molecular Mechanisms and Diagnosis of Mastocytosis
University of Michigan
Completed
NCT01126814 2015-06-24
A Study of Imatinib With Reinduction Chemotherapy Using Mitoxantrone, Etoposide and Cytarabine in Patients With Relapsed/Refractory C-kit Positive (AML) Acute Myeloid Leukemia
University Health Network, Toronto
Phase 1/2 Completed